HARBIN, China, Aug. 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced the appointment of Mr. William Wei Lee as an independent member of the Company's Board of Directors ("the Board") effective August 4, 2009. Mr. Jiang Qi-Feng resigned from the Board effective August 4, 2009. Following this appointment, China Sky One Medical's Board of Directors has seven members, four of whom are independent. Mr. Wei Lee also replaces Mr. Jiang as a member of the Audit Committee, Compensation Committee and Finance Committee of the Board of Directors, and as "audit committee financial expert" as defined by the SEC rules adopted pursuant to the Sarbanes-Oxley Act of 2002.
Mr. Wei Lee has over 15 years of experience in financial services and
government relations, including investments, joint ventures, mergers &
acquisitions and management consulting. From 2000 to 2002 he was a Senior
Associate at McKinsey Management Consulting Co. Ltd. and in 2003 he was a
Project Manager at Roland Berger Strategy Consultants Ltd. From 2004 to 2006,
he served as Director of Strategic Development at TNT N.V., an Amsterdam-based
provider of postal and logistics services, where he was responsible for M&A
and China business strategy. Since 2007, Mr. Wei Lee has been a Managing
Director with Transworld Capital Group, a U.S. investment service firm
specializing in cross-border M&A and fund raising between U.S. and China. In
2008, he served as Chief Operating Officer (on loan) for Legend Media
Corporation, a U.S.-listed company specializing in radio advertising in China.
Mr. Wei Lee earned a Master's degree in Political Science from North Illinoi
|SOURCE China Sky One Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved